Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE SME |
| SME IPO Issue Type | Book Build Issue |
| Total Issue Size | ₹27.56 Cr |
| Reserved for Market Maker | ₹0.00 Cr |
| Net Issue Size | ₹27.56 Cr |
| Fresh Issue | ₹26.17 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹115.00-123.00 per share |
| BSE Code | 544445 |
| Registrar | Maashitla Securities Pvt.Ltd. |
| Lead Managers | Sobhagya Capital Options Pvt.Ltd. |
| Allotment Status | |
| DRHP | |
| RHP | |
| Final Prospectus | |
| Anchor List | |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 2,000 shares · Multiples of 1,000 shares
Incorporated in 2019, Asston Pharmaceuticals Limited is engaged in the business of pharmaceuticals, specializing in exporting healthcare products globally.
The company offers a diverse range of products, including tablets, capsules, sachets, and syrups. Its product portfolio encompasses various therapeutic categories, such as analgesics, antibiotics, antifungals, vitamins, and more.
The company manufactures pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis, primarily working on a principle-to-principle approach with various marketers.
The company is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing.
Products:
As of 3 July 2025, the company has 46 Permanent employees and 6 contractual employees in various departments.
Competitive Strengths:
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit | 6.00 |
| 2 | Funding the incremental working capital requirements of the Company | 13.00 |
| 3 | Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company | 1.00 |
| 4 | General Corporate Purposes | 3.95 |
| 5 | Issue Expenses | 3.61 |
| Total | 27.56 |
| Period Ended | 31 May 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 31.83 | 28.12 | 20.26 | 13.69 |
| Total Income | 6.21 | 25.61 | 15.84 | 7.19 |
| Profit After Tax | 1.32 | 4.33 | 1.36 | 1.06 |
| EBITDA | 1.93 | 6.16 | 2.55 | 1.52 |
| NET Worth | 12.04 | 10.72 | 6.39 | 1.99 |
| Reserves and Surplus | 5.77 | 4.45 | 5.61 | 1.29 |
| Total Borrowing | 7.83 | 7.26 | 6.82 | 5.25 |
| Amount in ₹ Crore | ||||
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 50.56% |
| ROCE | 51.25% |
| Debt / Equity | 0.68% |
| RoNW | 40.36% |
| PAT Margin | 17.27% |
| EBITDA Margin | 24.60% |
| Price to Book Value | 12.07 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 6.90 | 9.32 |
| P/E (x) | 17.83 | 13.2 |
| Promoter Holding | 68.76% | 50.66% |
| Market Cap | ₹104.70 Cr. | |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Issue Management fees including fees and payment to other intermediaries such as Legal Advisors, Registrars and other out of pocket expenses. | 2.22 |
| 2 | Brokerage and selling commission fee for SCSBs, Sponsor Banks and Bankers to the Offer. Brokerage and selling commission and bidding charges for Members of the Syndicate, Registered Brokers, RTAs and CDPs | 0.08 |
| 3 | Printing & Stationery, Distribution, Postage, etc | 0.12 |
| 4 | Advertisement and Marketing Expenses | 1.16 |
| 5 | Stock Exchange Fees, Regulatory and other Expenses | 0.04 |
| Total | 3.61 |
